




Name	Dok Hyun Yoon	
Current Position	Associate professor	
Country	Korea	
Major Field	Lymphoma and Myeloma	

Educational Background

1991. 3 – 1996. 2	Bachelor of Science Department of Life Science Pohang University of Science and Technology Pohang, Korea
1996.3 – 1998.2	Master of Science Developmental Genetics Department of Life Science, Postgraduate School Pohang University of Science and Technology Pohang, Korea
1999. 3 – 2003. 2	M.D College of Medicine Yonsei University Seoul, Korea
2010. 3 – 2012. 2	Ph.D. of Medicine Postgraduate School University of Ulsan College of Medicine Seoul, Korea

Professional Experience

1998.3 – 1999.2	Researcher Laboratory of Drug Delivery System Korea Institute of Science and Technology Seoul, Korea
2011.3 – 2013.8	Full-time Clinical Instructor Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
2013.9 – 2018.8	Assistant professor



	Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
2018.9 – Present	Associate Professor Division of Oncology/Hematology Department of Internal Medicine Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
2022.4 – Present	Director CAR T-cell therapy center Asan Medical Center

Other Experience and Professional Memberships

2017.3 – 2018.8	Research Specialist Pediatric Hematology, Oncology and Blood Marrow Transplantation Program University of Minnesota Minneapolis, MN, USA
2018.5 – 2018.5	Observership Cellular Therapeutics Center Memorial Sloan Kettering Cancer Center New York, NY, USA

Main Scientific Publications

Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma.

Yoon DH, Koh Y, Jung M, Kwak JE, Shin EC, Hwang YK, Kim WS. *Transplant Cell Ther.* 2023 Apr;29(4):253.e1-253.e9.

BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.

Roh J, Cho H, Pak HK, Lee YS, Lee SW, Ryu JS, Chae EJ, Kim KW, Huh J, Choi YS, Jeong SH, Suh C, Yoon DH*, Park CS. *Mod Pathol.* 2022 Apr;35(4):480-488.

Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis.

Jeong H, Cho H, Kim H, Chae H, Lee JB, Lee K, Kim S, Lee SW, Ryu JS, Kim KW, Chae EJ, Huh J, Park CS, Yoon DH*, Suh C. *Blood Adv.* 2021 Apr 27;5(8):2142-2152

Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.

Yoon DH, Cao J, Chen TY, Izutsu K, Kim SJ, Kwong YL, Lin TY, Thye LS, Xu B, Yang DH, Kim WS. *J Hematol Oncol.* 2020 Mar 17;13(1):21



Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts):
Combination or Built-In CAR-T.

Yoon DH, Osborn MJ, Tolar J, Kim CJ. *Int J Mol Sci.* 2018 Jan 24;19(2):340.
